In this study we are correlating Color Doppler parameters (PI, RI and Vmax) with that of the different prognostic factors and association of these findings with that of 4 years Disease Free Survival (DFS) and Overall Survival (OS).
The present prospective clinical study conducted during December 2009 to May 2011 includes 92 patients of breast cancer. All patients were undergone Color Doppler examination before treatment and parameters RI, PI and Vmax were recorded. Out of 92 patients, 15 patients were incomplete treatment or not taken standard treatment. 17 patients were lost to follow up. Follow Up as per standard protocol. Taken from registry or telephonic interview. DFS and OS calculated from the time of completion of treatment. Appropriate statistics used for analysis.
Total 60 patients were available for analysis for 4 years. At 4 years 7(11%) had cancer related mortality and 17 (28%) had recurrences and metastasis. The correlation of Doppler parameter and tumor charecteristics with survival are tabulated in the below table. The correlation of PI, RI and Vmax with tumor size were 0.512, 0.742(P < 0.05) and 0.845(P < 0.05) respectively, with grade 0.453, 0.657(P < 0.05) and 0.445 respectively, with lymph nodes numbers 0.564, 0.756(P < 0.05) and 0.612 respectively.
|N= 60||DFS % (4 years)||OS % (4 years)|
|Stage T1T2T3T4||4122222||100.083.3068.1063.60||P < 0.05||100.091.6686.3686.36||P < 0.05|
|Hiostology Grade 1Grade 2Grade 3Grade 4||10271409||80.0077.7764.2855.55||P < 0.05||90.0092.5985.7177.77||P < 0.05|
|Lymph NodeN0N1N2N3||15281304||86.6071.4261.5375.00||P > 0.05||93.3389.2884.6175.00||P > 0.05|
|PI Grade 1Grade 2Grade 3Grade 4||0251817||- 80.0061.1170.58||P > 0.05||- 84.0088.8894.11||P > 0.05|
|RI Grade 1Grade 2Grade 3Grade 4||0371310||- 72.9776.9260.00||P < 0.05||- 91.8984.6180.00||P < 0.05|
|Vmax Grade 1Grade 2Grade 3Grade 4||2282010||100.071.4270.0070.00||P < 0.05||100.089.2890.0080.00||P < 0.05|
Doppler Parameters can be correlated with other prognostic indicator like tumor size and grade of the tumor and Lymph nodes. These can be used as prognostic indicator but further follow up large sample with multicentre trials is needed.
Clinical trial identification
All authors have declared no conflicts of interest.